Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus NCFM + lactobacillus rhamnosus HN001 + lactobacillus paracasei LPC-37 + bifidobacterium lactis HN019 + polydextrose
- Development stage
- Unknown
- Lead developer
- DuPont
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This synbiotic combination consists of four specific probiotic strains (*Lactobacillus acidophilus* NCFM, *Lactobacillus rhamnosus* HN001, *Lactobacillus paracasei* LPC-37, and *Bifidobacterium lactis* HN019) and the prebiotic fiber polydextrose. Developed by IFF (formerly DuPont Nutrition & Biosciences/Danisco), this blend is primarily marketed for metabolic health, weight management, and body fat reduction. The mechanism involves modulation of the gut microbiota, improvement of intestinal barrier function, and potential influence on metabolic pathways related to energy balance and satiety. Clinical studies, such as those investigating the "HOWARU Shape" formulation, have suggested benefits in reducing body fat mass and waist circumference in overweight individuals by altering the gut microbial composition and producing beneficial metabolites like short-chain fatty acids.
- Brand names
- HOWARU ShapeUltraFlora Control
- Other names
- HOWARU Shape synbiotic blendMetagenics UltraFlora Control
Beyond the preview
Go deeper on lactobacillus acidophilus NCFM + lactobacillus rhamnosus HN001 + lactobacillus paracasei LPC-37 + bifidobacterium lactis HN019 + polydextrose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus NCFM + lactobacillus rhamnosus HN001 + lactobacillus paracasei LPC-37 + bifidobacterium lactis HN019 + polydextrose.